Bank of America Securities Reiterated a Sell rating on Regeneron Pharmaceuticals (REGN), Lowered the PT

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Extremely Profitable Stocks to Buy Right NowOn July 22, Analyst Tim Anderson from Bank of America Securities reiterated a Sell rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) while reducing the price target from $535 to $504.

The bearish sentiment is primarily due to the challenges faced by the company’s Eylea franchise. Anderson expects the US sales of Eylea to decline significantly, leading to a below-market consensus EPS for 2025 and 2026. Moreover, the analyst is also concerned about the drug pricing pressures and increased competition from branded drugs and biosimilars. He noted the recent partial failure of Itepekimab, a key pipeline drug, which adds to the uncertainty around the company’s growth prospects.

Bank of America Securities Reiterated a Sell rating on Regeneron Pharmaceuticals (REGN), Lowered the PT

A pharmacist in a lab coat carefully analyzing a vial of medicine for its quality.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company that develops and commercializes treatments for serious diseases.

While we acknowledge the potential of REGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than REGN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.